MK-8527-010
Title:
A Phase 3, Randomized, Active-controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral MK-8527 Once Monthly as HIV-1 Preexposure Prophylaxis in Cisgender Women
Acronym:
MK-8527-010
Timeline:
2025 – 2027
Status:
Completed
Site Principal Investigators:
Imeldah Wakhungu, Dr. Dennis Kegode
Funder:
MSD
Objective:
The primary objective is to evaluate the efficacy of MK-8527 qm compared to FTC/TDF qd for the prevention of HIV-1 infection as assessed by the incidence rate per year of adjudicated HIV-1 infections.